Pay in 4 interest-free payments of $5.61 Learn more
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
We ship by special line shipping door to door
In the LEADER study with liraglutide, in the evaluation of cardiovascular events [n = 9340 patients, 50 years with established cardiovascular disease (coronary event, cerebrovascular event, or peripheral vascular disease), stage 3 chronic kidney disease, or chronic heart failure according to New York Heart Association class II or III or 60 years with at least one cardiovascular risk factor (CVRF)], liraglutide demonstrated a significant reduction in MACE by 13% at the expense of a reduction in cardiovascular mortality
.png)
Explore all of our IV Services
RDs can access webinars and print resources
Competition between injectable therapies Wegovy and Zepbound has brought prices down from over $1,000 a month when they were first introduced to $499 a month currently
M.AlharbiM
US$ 29.02
US$ 28.89
US$ 19.99
US$ 20.08
US$ 26.34
US$ 27.28
US$ 25.31
US$ 29.59
US$ 24.23
